Formulating poorly water soluble dru...
Miller, Dave A.

 

  • Formulating poorly water soluble drugs[electronic resource] /
  • 紀錄類型: 書目-語言資料,印刷品 : Monograph/item
    杜威分類號: 615.19
    書名/作者: Formulating poorly water soluble drugs/ edited by Robert O. Williams III, Alan B. Watts, Dave A. Miller.
    其他作者: Williams, Robert O.
    出版者: Cham : : Springer International Publishing :, 2016.
    面頁冊數: xiv, 779 p. : : ill., digital ;; 24 cm.
    Contained By: Springer eBooks
    標題: Drug development.
    標題: Drugs - Design.
    標題: Biomedicine.
    標題: Pharmaceutical Sciences/Technology.
    ISBN: 9783319426099
    ISBN: 9783319426075
    內容註: Route-Specific Challenges in Delivery of Poorly Water Soluble Drugs -- Optimizing the Formulation of Poorly Water Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle Size Reduction Techniques -- Solubilized Formulations -- Injectable Formulations of Poorly Water Soluble Drugs -- Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water Soluble Drugs -- Regulatory Considerations for Development and Commercialization of Poorly Water Soluble Drugs.
    摘要、提要註: The objective of this volume is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at minimum a working knowledge of each of the abovementioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop.
    電子資源: http://dx.doi.org/10.1007/978-3-319-42609-9
評論
Export
取書館別
 
 
變更密碼
登入